Summit Therapeutics (SMMT) Q4 2024 earnings summary

Executive summary

• Achieved major milestones for ivonescimab, including a new clinical trial collaboration with Pfizer to evaluate combinations with multiple ADCs in solid tumors, with trials starting mid-2025.

• Completed enrollment and received Fast Track designation for the Harmony/HARMONI global phase III trial in EGFR-mutated advanced NSCLC; top-line data expected mid-2025.

• Amended Harmony/HARMONI-3 to expand patient population, now including both squamous and non-squamous NSCLC, significantly increasing addressable patients.

• Initiated Harmony/HARMONI-7, a phase III trial of ivonescimab monotherapy versus pembrolizumab in first-line metastatic NSCLC with high PD-L1 expression.

• Over 2,300 patients treated with ivonescimab in clinical trials; 14 publications and five major conference presentations in 2024.

Financial highlights

• Ended 2024 with $412 million in cash and no debt, providing a strong financial position for ongoing and future trials.

• GAAP R&D expenses for 2024 were $150.8 million, up from $59.4 million in 2023; non-GAAP R&D expenses were $134.8 million, up from $55 million.

• GAAP G&A expenses rose to $60.5 million in 2024, mainly due to increased stock-based compensation; non-GAAP G&A expenses were $25.5 million.

• GAAP net loss for 2024 was $221.3 million, improved from $614.9 million in 2023; non-GAAP net loss was $170.3 million, compared to $600.8 million in 2023.

• $435 million in financing raised in 2024; paid off $31.8 million in principal and interest in Q4 2024.

Outlook and guidance

• Top-line data from the Harmony/HARMONI phase III trial expected mid-2025, covering both progression-free and overall survival.

• Plans to expand clinical development beyond NSCLC in 2025 and 2026, with additional investigator-sponsored trials and new indications.

• Ongoing and upcoming data readouts from Akeso-sponsored phase III trials in various tumor types expected throughout 2024.

• Clinical trials with Pfizer's ADCs in combination with ivonescimab to begin mid-2025.

• Additional details on pipeline expansion beyond lung cancer anticipated later in 2024.